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1  | INTRODUCTION
MpBC is a rare but aggressive subtype of invasive mammary car‐
cinoma accounting for less than 1% of all breast malignancies.1 It 
is a heterogeneous group characterized by the differentiation of 
the neoplastic epithelium into squamous cells and/or mesenchymal 
looking elements. The principal immunohistochemical characteris‐
tics of MpBC cells are that they are enriched with markers of epi‐
thelial‐mesenchymal transition and cancer stem cells.2,3 The World 
Health Organization (WHO) classifies MpBC into low‐grade adenos‐
quamous carcinoma, fibromatosis‐like metaplastic carcinoma, squa‐
mous cell carcinoma, spindle cell carcinoma, and carcinoma with 
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Abstract
Background: Metaplastic breast carcinomas (MpBCs) are rare, aggressive breast can‐
cers. Due to the scant literature of this disease most guidelines do not give recom‐
mendation for this entity. The aim of the study was to review the clinicopathologic 
features, treatment, and outcomes of the patients with MpBC treated at our 
institution.
Material and methods: We searched databases for patients with histologically con‐
firmed MpBC from 2002 to 2016.
Results: A	total	of	78	patients	with	MpBC	were	included	in	the	study.	All	histological	
material was reviewed by an experienced breast pathologist. Most tumors were 
grade 3 (83%) and triple negative (85%). Eighty‐two percent were node negative. 
Sixty‐four percent received adjuvant chemotherapy. The 5‐year disease free survival 
was 63% and 5‐year breast cancer specific overall survival was 61%. Tumor size and 
mixed metaplastic histology were associated with worse outcome in this patient 
group. One third of the patients (n = 28) had metastatic disease at initial presentation 
or developed metastases at follow‐up. The lungs were the most common site of first 
distant recurrence. Half (n = 14) of these patients received palliative chemotherapy. 
Of those only 6% (n = 2) had partial response and 18% had stable disease as best re‐
sponse to treatment. The median overall survival time with metastatic disease was 
only 3.4 months.
Conclusion: MpBC is an aggressive type of breast cancer with poor outcome despite 
low nodal involvement and aggressive local and systemic therapy. Tumor response to 
palliative systemic chemotherapy remains poor for MpBC patients.
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mesenchymal differentiation (chondroid, osseous, and other types 
of mesenchymal differentiation).1 MpBC can also present with histo‐
logic components of other conventional types of breast cancer such 
as invasive ductal carcinoma (IDC).
Patients with MpBC usually have larger, higher grade, and more 
often triple negative tumors compared with patients with IDC4‐6 and 
they usually carry a worse prognoses than IDC with similar stage and 
grade4,5,7 and even compared to other triple negative breast carci‐
nomas (TNBC).4,6,8‐10
According	 to	 previous	 studies	 the	 5‐year	 overall	 survival	 (OS)	
rate in MpBC patients has been 53.7%‐71% 4‐6,11 and the 5‐year dis‐
ease free survival (DFS) rate 45.5%‐64%4,6,11 compared with 5‐year 
OS of 81.2%‐88%4,5,12 and 5‐year DFS of 71.2%4 for conventional 
IDC.
Although	 the	knowledge	of	prognostic	 factors	of	MpBC	 is	 still	
limited, some factors have been shown to affect the outcome in 
MpBC. Lymph node metastasis,4‐6,13 lymphovascular invasion,14 
large tumor size,4,5,9,11 personal history of breast cancer,11 and 
positive surgical margins11,15 have previously been associated with 
inferior survival. In other breast cancers hormone receptor positiv‐
ity improves prognosis, but in the large study (n = 2338) made by 
Wright et al10 there was no difference in 5‐year survival between 
hormone‐positive and hormone‐negative tumors in MpBC. Studies 
from	 the	American	 SEERS	 database	 (n	=	2338	 and	 n	=	1501)	 have	
suggested that administration of radiotherapy is associated to im‐
proved survival in MpBC.12,16
Evidence for guiding management of patients with MpBC is lim‐
ited because there are no randomized clinical trials to guide therapy 
selection. Currently MpBC is treated using algorithms developed 
for other histologic subtypes of invasive breast carcinoma. There 
are only small studies available regarding its response to systemic 
chemotherapy and they have indicated poor responsiveness of this 
disease to systemic agents. In a study of 21 patients receiving neo‐
adjuvant chemotherapy the pathologic complete response rate was 
only 10%.17 In another study of 11 patients in advanced disease 
18.2% experienced a partial response.18
Further study is required to optimize outcomes for patients with 
this rare breast cancer subtype.
2  | MATERIAL AND METHODS
This study was approved by the local ethical committee. The pathol‐
ogy databases were searched over a 15‐year period (2002‐2016) 
for patients with a histologically confirmed diagnosis of metaplas‐
tic carcinoma who were treated at the Helsinki University Hospital 
Comprehensive	Cancer	Centre.	All	the	cases	were	reviewed	by	a	
breast	pathologist	(PH)	to	verify	MpBC	and	classify	them.	A	total	
of 78 patients fulfilled the criteria and were included in this study. 
Data regarding clinicopathologic features, treatment, recurrence, 
and survival were obtained. Her2 positivity was assessed by im‐
munohistochemistry and all 2+ or 3+ scores were certified by fluo‐
rescent in situ hybridization. ER‐ and PR‐positivity were defined 
as any nuclear labeling in 10% of tumor cells or higher. The his‐
tological grade was determined according to the Elston and Ellis 
modification of the Scarff‐Bloom‐Richardson grading system.19 
Histologic subtypes were classified according to WHO classifica‐
tion. MpBCs presenting with mixed metaplastic components were 
classified into mixed metaplastic carcinomas and MpBCs present‐
ing with a conventional type of breast cancer were classified into 
mixed type.
Loco‐regional recurrence was defined as tumor recurrence in the 
breast, ipsilateral axilla, thoracic wall, supraclavicular fossa, or para‐
sternal region. Distant recurrence was defined when the recurrence 
occurred at any other site.
Survival time, in years, was calculated from the date of oper‐
ation, until the date of death, with patients who were alive cen‐
sored at the date of last follow‐up. DFS was calculated as the time 
from operation to the time of first documentation of breast cancer 
recurrence at any site (ie loco‐regional or distant), or death due to 
breast cancer, whichever occurred first. Survival probabilities at 
5 years were estimated using the Life Table method. Univariate 
and multivariate Cox regression analyses were performed to eval‐
uate the prognostic impact of various clinicopathologic features 
on OS and DFS. The hazard ratios (HRs) were estimated with 95% 
confidence intervals (CIs).
Tumor response assessment in metastatic setting was performed 
by using RECIST guideline (version 1.1).20 Time to progression (TTP) 
was calculated from the first treatment date until the date of first 
progression.
Association	 between	 tumor	 type	 and	 clinical	 characteristics	
was tested with the Chi‐square test or Fisher's exact test if appli‐
cable. Differences in survival and local recurrence by radiotherapy 
were tested using the log‐rank test. The significance level was set 
at P	≤	0.05.
3  | RESULTS
3.1 | Clinicopathologic features and primary 
treatment
78 female patients with a diagnosis of MpBC were identified. The 
clinicopathologic features and primary treatment of these pa‐
tients and their tumors are summarized in Table 1. Most patients 
had grade III (83%), T2 (46%), N0 (82%), and triple negative disease 
(85%). Clinicopathologic features and primary treatment by sub‐
group is shown in Supplementary Table S1. The mixed type tumors 
were associated with more advanced T‐stage (P = 0.2), node posi‐
tivity (P < 0.0001) and distant metastases at diagnosis (P = 0.045). 
The most common single histologic subtype was squamous cell 
carcinoma (26%). 28 patients had metastatic disease at presenta‐
tion or during follow‐up. The most common site of metastasis was 
the lungs (n = 20), followed by lymph nodes (n = 7), liver (n = 6), and 
bone (n = 6). Loco‐regional recurrence without distant metastasis 
occurred in 5% (n = 4) of the patients. The most common site of loco‐
regional recurrence was the thoracic wall (n = 3).
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3.2 | Survival analysis
Five year DFS was 63%, 5‐year OS was 52%, and 5‐year breast can‐
cer specific OS was 61%, with a median follow‐up of 6.3 years (range 
0.2‐14.4). Three year DFS was 63% and breast cancer specific OS 
68% respectively. Univariate Cox regression analysis for associations 
between clinicopathologic features and OS and DFS are presented in 
Table 2. Tumor size and mixed subtype were associated with worse 
DFS	 and	OS	 in	 univariate	 analyses.	 Age,	 grade,	 nodal	 status,	 hor‐
mone receptor, and HER2 ‐status did not have statistically significant 
association with survival outcomes. Tumor size and MpBC subtype 
were independent prognostic factors for OS and DFS in multivariate 
analysis. Kaplan‐Meier analyses for associations between histologic 
subtypes and DFS and OS are presented in Figure 1. Radiotherapy 
provided an OS (P = 0.045) but not a loco‐regional recurrence‐free 
survival (P = 0.489) benefit.
TA B L E  1   Clinicopathologic and treatment characteristics
Characteristics No. (%)
Age	at	primary	diagnosis	(y)
Median (range) 66.6 (23.9‐91.7)
Menopause status (n = 74)
Premenopausal 12 (16)
Postmenopausal 62 (84)
Tumor size (mm)
Median (range) 30 (5.0‐130.0)
Tumor size (T) (n = 76)
T1 22 (29)
T2 35 (46)
T3 14 (18)
T4 5 (7)
Grade
1 3 (4)
2 10 (13)
3 65 (83)
Lymph node status (n = 71)
N0 58 (82)
N1 8 (11)
N2 2 (3)
N3 3 (4)
Metastasis at diagnoses
No 76 (97)
Yes 2 (3)
ER status
Positive 9 (12)
Negative 69 (88)
PR status
Positive 2 (3)
Negative 76 (97)
Her2
Positive 3 (4)
Negative 75 (96)
Triple negative
Yes 66 (85)
No 12 (15)
Histologic subtype
Low‐grade adenosquamous 2 (3)
Squamous 20 (26)
Spindle 17 (22)
Chondroid differentiation 11 (14)
Osseous differentiation 2 (3)
Fibromatosis‐like 0 (0)
Mixed metaplastic 9 (12)
Mixed type 17 (22)
Characteristics No. (%)
Type of breast surgery
Mastectomy 48 (62)
Breastconserving 29 (37)
Biopsy 1 (1)
Type of axillary surgery
Sentinel node biopsy 33 (42)
Dissection 38 (49)
None 7 (9.0)
Chemotherapy (adjuvant)
Yes 50 (64)
No 28 (36)
Chemotherapy (neoadjuvant)
Yes 2 (3)
No 76 (97)
Radiotherapy
Yes 47 (60)
No 31 (40)
Radiotherapy target (n = 47)
Scar 20 (43)
Residual breast 27 (57)
Axilla 12 (26)
Clavicle fossa 13 (28)
Parasternal region 4 (9)
Endocrine therapy
Yes 8 (10)
No 70 (90)
Anti‐Her2	therapy
Yes 3 (4)
No 75 (96)
ER, oestrogen receptor; PR, progesterone receptor; HER2, human epi‐
dermal growth factor receptor 2; MpBC, metaplastic breast carcinoma.
TA B L E  1   (Continued)
(Continues)
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3.3 | Systemic treatment of metastatic MpBC
Fourteen of the 28 patients with metastatic disease received 
palliative systemic chemotherapy and one of them received 
palliative endocrine therapy. The chemotherapy regimens, sub‐
types and response details of these 14 patients are detailed in 
Table	3.	A	total	of	34	chemotherapy	regimens	were	administered	
with the median number of chemotherapy lines being two. Only 
two patients had a partial response (PR) to first and second line 
chemotherapy respectively. The two responders (the latter being 
a	 patient	 with	 a	 BRCA2‐mutation)	 were	 treated	with	 cisplatin‐
capecitabine (TTP 131) and FEC (TTP 270 days). The patient 
with	 a	 BRCA2‐mutation	 also	 had	 stable	 disease	 (SD)	 receiving	
docetaxel as first line treatment (TTP 122 days), capecitabine 
as third line treatment (TTP 140 days), capecitabine‐vinorelbine 
as fourth line treatment (TTP 143), FEC as fifth line treatment 
(TTP 191 days) and carboplatin‐gemcitabine as sixth line treat‐
ment (TTP 121 days). In addition, one other patient had SD‐re‐
sponse receiving FEC as second line treatment (TTP 235 days). 
One of the responders had squamous histologic subtype and 
the	other	one	had	mixed	histologic	 type.	All	 the	other	patients	
had either progressive (PD) or non‐evaluable (NE) disease. Of 
the four patients with non‐evaluable disease, three died shortly 
after the treatment and one had clinically evaluated progression. 
The patient receiving endocrine therapy as first line treatment 
had PD on letrozole (TTP 69 days). The median overall survival 
time with metastatic disease was 3.4 months (range, 0.07‐31.2), 
6.4 months (range, 0.2‐31.3) for those who had (n = 15), and 
1.1 months (range, 0.07‐16.4) for those who had not (n = 13) re‐
ceived palliative chemotherapy or endocrine therapy.
In addition, we assessed the effect of palliative radiotherapy and 
detected only few radiological or symptomatic responses. Instead, 
most of the patients died shortly after the treatment due to aggres‐
sive metastatic disease (data is not shown).
4  | DISCUSSION
We present the clinicopathologic features, treatment, and clinical 
outcomes of 78 patients with MpBC treated at our institution. In 
our series 82% of the patients were node‐negative and 46% had 
T2 disease. Most of the tumors were poorly differentiated (83%), 
and triple negative (85%). Our findings are consistent with previous 
studies which suggested that the majority of MpBC tumors are triple 
negative (48%‐86%) and node‐negative (51%‐79%).4,6,11,13,15	Also,	in	
previous studies most of the patients have had Grade III, T2 disease, 
with the rates of 77%‐86% and 52%‐62%.5,11
Our study confirms the poor prognosis of this disease with 
5 years OS of only 52%, which is to be compared with the 5 years 
overall breast cancer survival of 86%‐88% between 2000 and 2014 
in the Nordic Cancer Registry.21 The findings are similar to those 
reported by Song et al4with a 5‐year OS of 54.5% and DFS of 45.5% 
(n = 55) and Cimino‐Matthews et al11 with a 5‐year OS of 69%, re‐
currence‐free survival (RFS) of 64% and distant metastasis‐free sur‐
vival (DMFS) of 75% (n = 45). The pattern of recurrence seems to be 
different from other types of breast cancer with the lungs being the 
most common site of first distant metastasis while bone usually is 
the most common site in general breast cancer materials.22
In the present study, only tumor size and mixed metaplastic his‐
tology	were	associated	with	inferior	outcome.	Also,	in	other	studies	
tumor size has been a significant prognostic factor.4,5,9,11 Histologic 
subtype has also previously been reported to be associated with 
outcome12; as in the present study the group of spindle and mixed 
spindle and squamous subtypes had inferior breast cancer specific 
TA B L E  2   Univariate and multivariate Cox regression analyses for association of clinicopathologic features with clinical outcome
Characteristics
Overall survival Disease free survival
Univariate Multivariate Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Age	(continuous) 1.02 (0.99‐1.05) 0.142   1.02 (0.99‐1.05) 0.197   
Tumor size (cm) 1.24 (1.10‐1.39) 0.000 1.23 (1.09‐1.34) 0.001 1.22 (1.08‐1.38) 0.001 1.21 (1.08‐1.37) 0.001
Grade (continuous) 1.63	(0.65	−4.08) 0.301   1.53 (0.63‐3.72) 0.353   
Nr of metastatic 
lymph nodes
1.00 (0.93‐1.07) 0.895   1.04 (0.99‐1.08) 0.133   
ER‐status 
Positive vs negative
0.84 (0.26‐2.80) 0.782   0.82 (0.25‐2.71) 0.741   
PR‐status 
Positive vs negative
0.05 (0.00‐220.5) 0.477   0.05 (0.00‐331) 0.499   
HER2‐status 
Positive vs negative
0.05 (0.00‐93.4) 0.428   0.05 (0.00‐354) 0.502   
Subtype 
Mixed vs nonmixed
2.82 (1.34‐5.94) 0.006 2.47 (1.15‐5.29) 0.020 2.96 (1.42‐6.2) 0.004 2.68 (1.27‐5.69) 0.010
CI, confidence interval; ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; PR, progesterone receptor.
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outcome compared to a group of matrix producing and squamous 
subtypes.	Also,	Cimino‐Matthews	et	al9 reported that mixed histo‐
logic subtype was associated with worse outcome. Our findings also 
suggested radiotherapy to be associated with improved survival, 
however, this might be due to selection bias.
Only 5% of our patients experienced loco‐regional recurrence. 
Compared with previous studies the loco‐regional recurrence rate 
in our series was low. In the study by Edenfield et al15 40% devel‐
oped metastatic disease and 12% loco‐regional recurrence despite 
most patients having T1 disease (40%) and 60% receiving radiother‐
apy (n = 25). The recurrence rates were similar in a study by Song 
et al4 (n = 55) with 23 patients (42%) developing metastatic disease 
and 10 patients (18%) loco‐regional recurrence. In the latter series 
the higher recurrence rate may at least partly have been due to the 
more advanced stage as well as less aggressive local treatment, as 
the median tumor size was larger than in our study (5 cm vs 3 cm), 
fewer had node‐negative disease (64% vs 82%) and fewer patients 
received radiotherapy (49% vs 60%).
F I G U R E  1  A,	Disease‐free	survival	by	
histologic subtype (P = 0.027*). B, Overall 
survival by histologic subtype (P = 0.059*). 
*P values were obtained from log rank 
test
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We found the response to palliative systemic therapy in meta‐
static MpBC poor. PR as best response was seen only in 6% of the 
cases and SD in 18% of the cases. The few responses were seen 
in the patients treated with anthracyclines ie FEC‐regimen and 
capecitabine‐containing	 regimes.	 Also,	 in	 some	 previous	 studies	
capecitabine has provided survival benefit in patients with TNBC.23
Palliative systemic treatment for patients with metastatic dis‐
ease has been ineffective also in previous studies, although the 
number of published cases still remains low. In one study of 12 pa‐
tients with metastatic MpBC who received palliative chemotherapy, 
only 2 patients (16.7%) had PR and all the other 10 patients (83.3%) 
experienced PD. One of the responders received oral uracil‐Tegafur 
and the other was treated with weekly paclitaxel and 24‐h high‐dose 
infusional fluorouracil and Leucovorin.18 In another study of 23 pa‐
tients who received palliative chemotherapy, mainly consisting of 
anthracyclins, carboplatin, taxanes, capecitabine, and vinorelbine, 
only 5 patients (21.7%) had PR and another 5 patients (21.7%) had 
SD.4 Finally in a study of 25 patients with metastatic MpBC, the ob‐
jective response rate (ORR) was 38.9%, which is in contrast with the 
other results. Subgroup analysis did not show significant differences 
in ORR between the chemotherapy regimens and the chemorespon‐
siveness of MpBC was similar to triple negative IDC.6
In conclusion, MpBC is an extremely aggressive type of breast 
cancer with poor outcome despite of low nodal involvement and ag‐
gressive local and systemic therapy. We could verify that mixed his‐
tologic subtypes and large tumor size were poor prognostic markers. 
Given the poor prognoses and reduced response to treatment for 
MpBC, new treatment paradigms need to be identified.
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